N-Care Project: Enhancing Asian-Pacific Collaboration

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

70 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-02-17

Study Completion Date

2032-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Through Asian-Pacific multinational collaboration, we aim to utilize third-generation genome sequencing to rapidly diagnose genetic diseases in critically ill infants and young children, achieving the goal of early diagnosis for targeted treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Rapid Genetic Diagnosis Employing Next Generation Sequencing for Critical Illness in Infants and Children

NCT03175692

Congenital Metabolic Disorder Acute Disease

UNKNOWN

Genomic Study of Congenital Malformation

NCT01250613

Genomic Aberrations in Patients Diagnosed as Congenital Malformation With Unknown Etiology

UNKNOWN

Use Cord Blood Single Nucleotide Polymorphism to Predict the Later Development of Atopy and Allergy

NCT00444327

Atopy Allergic Disease

UNKNOWN

NGS Strategy Effectiveness in Molecular Diagnosis

NCT03557567

Multiple Osteochondroma Osteogenesis Imperfecta

COMPLETED

Child Development and Genetic Biomarkers

NCT04660942

Child Development

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A group of individuals with specific characteristics was selected. Genetic studies were arranged for participants who provided their consent.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Whole Genome Sequencing Genetic Disease Critical Care, Intensive Care Nanopore Sequencing

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Genetic study with nanopore sequencing

The study targets critically ill children under 18 months of age, employing third-generation genome sequencing technology to complete long-read sequencing within 8-11 days, analyzing single nucleotide variants, small insertions/deletions, and structural variations. Through this research, we aim to enhance diagnostic accuracy, enabling ICUs to provide personalized and precision care and treatment based on genetic information, thereby ensuring a greater level of health security for these children. We only draw 3-5cc whole blood once for exam.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age: infant/newborn less than 18 months
2. Admitted to intensive care unit
3. At least one of the following conditions A. Specific anomaly highly suggestive of a genetic etiology

* Multiple birth defects
* Single major malformation that required intervention (surgery or medication)
* Significantly abnormal EKG
* Significant hypotonia

B. Children with high-risk stratification on assessment of a Brief Resolved Unexplained Event (BRUE) with any of the following:

* Recurrent severe infection events
* Recurrent or prolonged seizures
* Unexplained cardiopulmonary resuscitation (CPR)
* Suspect inborn error of metabolism

Exclusion Criteria

1. Infants with a definitive non-genetic diagnosis: ex as below A. An infection with normal response to therapy B. Isolated prematurity C. Transient hypoglycemia D. Isolated unconjugated hyperbilirubinemia E. Isolated Transient Neonatal Tachypnea F. Those where the clinical course can be explained without genetic testing
2. Confirmed genetic diagnosis explains illness
3. Lack of consent: Families who do not consent to genetic testing or data sharing.
4. Infants without sufficient DNA sample quality/quantity: Where the quality or quantity of the DNA sample is inadequate for sequencing.

Maximum Eligible Age

18 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No